Daily blood glucose measures in phase 3 clinical trials demonstrated better stability
In a new analysis1 of late stage clinical trials, adults with type 2 diabetes treated with Sanofi's Toujeo® (insulin glargine 300 Units/mL, Gla-300) achieved better blood glucose stability than those on insulin glargine 100 Units/mL (Lantus®, Gla-100). September 13, 2017